pharmadog
News
when
  • Latest
  • Archive
by source
  • All Sources
  • Sources Page
Jobs
department
  • Clinical
  • Regulatory
  • Medical Affairs
  • Commercial
  • R&D / Discovery
  • Biostatistics / Data
  • Manufacturing / CMC
  • Market Access
therapeutic area
  • Oncology
  • Immunology
  • Neuroscience
  • Cardiovascular
  • Metabolic
  • Rare Disease
  • Infectious Disease
location & type
  • Remote Only
  • US Only
  • California
  • Massachusetts
  • Internships
  • Phase 3 Roles
  • All Jobs →
Sign InSubscribe
pharmadog

fetch the data · sniff the signal

Discover
  • Jobs
  • News
Hubs
  • Topics
  • Patent cliff
  • Publications
Tools
  • Compare
  • Search
  • Bookmarks
Trust
  • About
  • Sources
  • Contact
Legal
  • Privacy
  • Terms
  • Pricing

© 2026 pharmadog.xyz

made by humans and a good dog

  • home
  • jobs
  • news
  • search
Endpoints·Jun 9·1 min read
save

WuXi AppTec re-added to Pentagon list of firms linked to Chinese military

Jun 9, 2026·read at Endpoints ↗RegulatoryNegative

WuXi AppTec has been placed again on the Pentagon's updated list of companies that have ties to the Chinese military, according to a June 9, 2026 report.

The inclusion marks renewed scrutiny of the contract research organization, which provides manufacturing and development services to pharmaceutical and biotechnology companies.

Analysts note that the listing could raise regulatory and partnership risks for WuXi AppTec and its customers, though no specific actions have been detailed.

source

This writeup was produced by pharmadog from original reporting by Endpoints.

Original headline: “WuXi AppTec added to Pentagon's list of companies linked to Chinese military”

read at Endpoints ↗
83 words · retrieved Jun 9
sharex / twitterlinkedin

comments(0)

5-min edit window · permanent after that
sign in to leave a comment · permanent archive after 5 minutes
no comments yet — first sniff?

companies & drugs in this story

topics
CRO/CDMO

related stories

  • 2h agoNovartis may cut around 130 in Switzerland while relocating biologics productionBioSpace
  • Jul 28The FDA was all in on AI. Will that change?BioPharma Dive
  • Jul 28As pharma descends on China for deals, BIOSECURE Act raises intellectual property riskBioSpace
  • Jul 27From confidence to capital: Positioning biotech for the next growth cycleBioPharma Dive
  • Jul 27FDA has recommitted to adcomms—but to what end?BioSpace